92 patents
Page 2 of 5
Utility
Treatment of congenital adrenal hyperplasia
26 Apr 22
CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Dimitri E. Grigoriadis
Filed: 4 Aug 21
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
10 Feb 22
Provided is a method of administering a vesicular monoamine transport 2 (VMAT2) inhibitor to a patient in need thereof, wherein the patient experiences one or more clinically significant parkinson-like signs or symptoms.
Grace S. Liang, Eiry W. Roberts, Dao Tuyet Thai-Cuarto, Barbara Scholz
Filed: 21 Oct 21
Utility
CRF1 Receptor Antagonist, Pharmaceutical Formulations and Solid Forms Thereof for the Treatment of Congenital Adrenal Hyperplasia
27 Jan 22
Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Formula 1), or a pharmaceutically acceptable salt thereof.
Robert H. FARBER, Gordon Raphael LOEWEN, Xiaoping ZHANG, Nagdeep GIRI, Jean L. CHAN, Scott STIRN, Brian SAYERS, Graeme TAYLOR, Christina Marie COSTA, Stacy PARKS, Anthony D. VICKERY, Kristie M. DOWNING, Kingsley IYOHA, Ayanda NGWENYA-JONES, Anne CHARLIER, Gurvinder Singh MEHTON
Filed: 6 Dec 19
Utility
Treatment of Congenital Adrenal Hyperplasia
25 Nov 21
CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Dimitri E. Grigoriadis
Filed: 4 Aug 21
Utility
Methods for the Administration of Comt Inhibitors
4 Nov 21
Provided are methods of administering a catechol-O-methyltransferase (COMT) inhibitor chosen from opicapone, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is already being administered quinidine or is suffering from a disease or disorder treatable by quinidine.
Gordon LOEWEN, Grace LIANG, Evan SMITH
Filed: 4 Oct 19
Utility
N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -Carboxamide Derivatives and Related Compounds As Muscarinic Receptor 4 (M4) Antagonists for Treating Neurological Diseases
4 Nov 21
Nicole Harriott, Nicholas Pagano
Filed: 26 Apr 21
Utility
Gonadotropin-releasing Hormone Receptor Antagonists and Methods Relating Thereto
16 Sep 21
Graham BEATON, Mi CHEN, Timothy Richard COON, Todd EWING, Wanlong JIANG, Willy MOREE, Martin ROWBOTTOM, Warren WADE, Liren ZHAO, Richard LOWE, Nicole SMITH, Neil ASHWEEK, Yun-Fei ZHU
Filed: 18 Dec 20
Utility
Methods for the Administration of Comt Inhibitors
22 Jul 21
Provided are methods of administering a catechol-O-methyltransferase (COMT) inhibitor chosen from opicapone, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a CYP2C8 substrate, such as repaglinide.
Gordon LOEWEN, Grace LIANG, Evan SMITH
Filed: 1 Apr 21
Utility
[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
6 Jul 21
Neil Ashweek, Nicole Harriott
Filed: 22 Jan 20
Utility
Treatment of Hyperkinetic Movement Disorders
1 Jul 21
Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 15 Sep 20
Utility
Methods for the administration of certain VMAT2 inhibitors
22 Jun 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 2D6 (CYP2D6) inhibitor.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 8 May 20
Utility
VMAT2 inhibitor compounds and compositions thereof
22 Jun 21
Nicole Harriott, Donald Hettinger, Shawn Branum, Jeffrey C. Culhane
Filed: 17 Apr 18
Utility
Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases
15 Jun 21
Nicole Harriott, Nicholas Pagano
Filed: 4 Nov 16
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
10 Jun 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
Christopher F. O`Brien, Haig P. Bozigian
Filed: 17 Dec 20
Utility
Methods for the administration of certain VMAT2 inhibitors
8 Jun 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.
Grace S. Liang, Christopher F. O'Brien, Dao Tuyet Thai-Cuarto
Filed: 3 Aug 20
Utility
High dosage valbenazine formulation and compositions, methods, and kits related thereto
8 Jun 21
Solid pharmaceutical compositions with high drug loading are provided.
Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O{grave over ( )}Brien
Filed: 19 Oct 20
Utility
Substituted triazoles and methods relating thereto
1 Jun 21
Neil J. Ashweek, John P. Williams, Deborah Slee, Manisha Moorjani
Filed: 4 Jun 20
Utility
Treatment of Congenital Adrenal Hyperplasia
13 May 21
CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Dimitri E. Grigoriadis
Filed: 20 Oct 20
Utility
Methods for the administration of certain VMAT2 inhibitors
4 May 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient has mild, moderate, or severe hepatic impairment.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 8 May 20
Utility
Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
22 Apr 21
Provided herein are methods for treating schizophrenia or schizoaffective disorder by administering to a subject in need thereof (,S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.
Christopher F. O`Brien, Dimitri E. Grigoriadis
Filed: 3 Jun 20